Cargando…

A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report

PURPOSE: With this study, we intended to construct a personalized drug-screening system for platinum-resistant ovarian cancer patients by consulting a patient’s medical history, data derived from gene mutation detection, and drug screening results derived from mini-PDX (patient-derived xenograft) mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yunke, Xu, Jing, Li, Ke, Wang, Jing, Dai, Yilin, Kang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020460/ https://www.ncbi.nlm.nih.gov/pubmed/33833569 http://dx.doi.org/10.2147/CMAR.S276799

Ejemplares similares

Identification of WTAP-related genes by weighted gene co-expression network analysis in ovarian cancer
por: Wang, Jing, et al.
Publicado: (2020)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020)

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
por: Beale, P J, et al.
Publicado: (2000)

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer
por: Sinsuwan, Woraporn, et al.
Publicado: (2023)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells
por: Roberts, D, et al.
Publicado: (2005)

Establishment and Characterization of Acquired Resistance to Platinum Anticancer Drugs in Human Ovarian Carcinoma Cells
por: Misawa, Toshiya, et al.
Publicado: (1995)

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
por: Severi, Leda, et al.
Publicado: (2018)

Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer
por: Mensah, Lawrence B., et al.
Publicado: (2019)

Predicting response to platinum and non-platinum drugs through bioluminescence resonance energy transfer (BRET) based bio-molecular interactions in platinum resistant epithelial ovarian cancer
por: Bishnu, Aniketh, et al.
Publicado: (2021)

Platinum resistance in breast and ovarian cancer cell lines
por: Eckstein, Niels
Publicado: (2011)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Altered glutamine metabolism in platinum resistant ovarian cancer
por: Hudson, Chantelle D., et al.
Publicado: (2016)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Advances in drug delivery system for platinum agents based combination therapy
por: Kang, Xiang, et al.
Publicado: (2015)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
por: Xu, Manman, et al.
Publicado: (2022)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
por: Janzen, D. M., et al.
Publicado: (2015)

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study
por: Michalak, Marcin, et al.
Publicado: (2020)

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
por: Rae, Sophie, et al.
Publicado: (2022)

A novel drug–drug nanohybrid for the self-delivery of porphyrin and cis-platinum
por: Shan, Changfu, et al.
Publicado: (2019)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

Oral melphalan as a treatment for platinum-resistant ovarian cancer
por: Hasan, J, et al.
Publicado: (2003)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7ij1l1j59v5n9lfvfut9rgd4va